A novel synthetic antimicrobial peptide (GK-19) derived from scorpion venom killed both drug-resistant bacteria and fungi while showing negligible toxicity to mammalian cells, and significantly improved healing of MRSA and Candida skin infections in mice.
Dual anti-bacterial and anti-fungal activityGK-19 killed both drug-resistant bacteria (including MRSA) and fungi (including Candida) in vitro and significantly improved infected burn wound healing in mice — with negligible toxicity to mammalian cells.
What the researchers found
GK-19 demonstrated broad-spectrum antimicrobial activity against five bacterial species (including Gram-positive and Gram-negative) and three fungal species by disrupting microbial cell membranes. Key advantages over the parent scorpion peptide AamAP1:
- Negligible toxicity to mammalian cells (the original AamAP1 was strongly toxic)
- Low hemolytic activity (does not destroy red blood cells)
- High stability in blood plasma
In scalded mouse models with skin and soft tissue infections, GK-19 showed significant antimicrobial effects and improved wound healing when infections were induced by either MRSA (methicillin-resistant Staphylococcus aureus) or Candida albicans.
Why it matters
MRSA and Candida infections are major clinical challenges, particularly in burn patients and immunocompromised individuals. Antibiotic-resistant infections kill over 1.2 million people annually worldwide. GK-19 offers a dual advantage: it kills both bacteria and fungi (most antibiotics target only one or the other) through physical membrane disruption that pathogens cannot easily evolve resistance against. The successful reduction in toxicity from the parent scorpion peptide demonstrates that venom-derived peptides can be engineered into safe therapeutics.
How the study worked
Researchers designed GK-19 as a synthetic peptide based on the scorpion venom peptide AamAP1 and its derivatives. In vitro testing evaluated antimicrobial activity against five bacterial and three fungal species using standard susceptibility assays. Mechanism of action was confirmed through membrane disruption studies. Safety was assessed via mammalian cell toxicity assays, hemolysis testing, and plasma stability measurements. In vivo efficacy was evaluated using a scalded (burn wound) mouse model combined with skin and soft tissue infections induced by either MRSA or Candida albicans, measuring both microbial clearance and wound healing.
What this study cannot tell us
While the mouse burn wound model is clinically relevant, it may not fully predict human responses. Specific MIC (minimum inhibitory concentration) values and comparative potency against standard antibiotics/antifungals are not detailed in the abstract. The study does not address manufacturing scale-up, cost, or formulation for clinical delivery. Long-term safety, pharmacokinetics, and potential for allergic reactions to a scorpion-derived peptide were not evaluated. The in vivo testing appears limited to topical application for skin infections — systemic use was not assessed.
How to read the evidence
This is a preclinical study with comprehensive in vitro characterization (antimicrobial spectrum, mechanism, safety profile) and in vivo validation in a clinically relevant burn wound infection model. The progression from bench to animal model with both bacterial and fungal infections is a strength, though human clinical data is needed.
When this study was published
Published in 2022, this is a recent study in the active field of antimicrobial peptide drug development. Scorpion venom-derived therapeutics continue to attract research interest as antibiotic resistance worsens.
The bigger picture
Venom-derived peptides are an increasingly important source of drug candidates. Scorpions, spiders, snakes, and cone snails have evolved highly potent antimicrobial and bioactive peptides over millions of years. The challenge has always been separating therapeutic activity from toxicity. GK-19 exemplifies the modern approach of using natural peptides as starting points, then engineering them for safety and stability. With antibiotic resistance accelerating and few new antibiotics in the pipeline, these antimicrobial peptides represent a critical alternative therapeutic class.
Questions still open
- Could GK-19 be effective against other drug-resistant organisms beyond MRSA and Candida?
- Is GK-19 suitable for systemic administration (injection) for deep-seated infections, or is it limited to topical wound treatment?
- How does GK-19's antimicrobial potency and cost compare to currently available topical antimicrobials like mupirocin or silver sulfadiazine?
Common questions
Why use scorpion venom to make antibiotics?
Can bacteria develop resistance to peptide antibiotics like GK-19?
Read the original research
Antibacterial and Antifungal Properties of a Novel Antimicrobial Peptide GK-19 and Its Application in Skin and Soft Tissue Infections Induced by MRSA or Candida albicans.
Pharmaceutics, 14(9)
Citation
Song, Chenghua; Wen, Ruichao; Zhou, Jiaxuan; Zeng, Xiaoyan; Kou, Zi; Zhang, Jia; Wang, Tao; Chang, Pengkang; Lv, Yi; Wu, Rongqian. (2022). Antibacterial and Antifungal Properties of a Novel Antimicrobial Peptide GK-19 and Its Application in Skin and Soft Tissue Infections Induced by MRSA or Candida albicans.. Pharmaceutics, 14(9). https://doi.org/10.3390/pharmaceutics14091937